General Information of Drug (ID: DMN37KO)

Drug Name
o-hydroxyatorvastatin Drug Info
Synonyms BMS-243887
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9808225
CAS Number
CAS 214217-86-4
TTD Drug ID
DMN37KO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting HMG-CoA reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [3]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [4]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [5]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [6]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [7]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [4]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [8]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [4]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [9]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6705).
2 Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 2008 Jul 10;51(13):3804-13.
3 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
4 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
6 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
7 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
8 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
9 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.